EA201692161A1 - Прогемостатические белки для лечения кровотечений - Google Patents

Прогемостатические белки для лечения кровотечений

Info

Publication number
EA201692161A1
EA201692161A1 EA201692161A EA201692161A EA201692161A1 EA 201692161 A1 EA201692161 A1 EA 201692161A1 EA 201692161 A EA201692161 A EA 201692161A EA 201692161 A EA201692161 A EA 201692161A EA 201692161 A1 EA201692161 A1 EA 201692161A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
proteins
progemostatic
bleeding
factor
Prior art date
Application number
EA201692161A
Other languages
English (en)
Other versions
EA037991B1 (ru
Inventor
Даниэль Верхуф
Питер Х. Рейтсма
Меттина Х.А. Бос
Original Assignee
Академиш Зикенхёйс Лейден
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Академиш Зикенхёйс Лейден filed Critical Академиш Зикенхёйс Лейден
Publication of EA201692161A1 publication Critical patent/EA201692161A1/ru
Publication of EA037991B1 publication Critical patent/EA037991B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6432—Coagulation factor Xa (3.4.21.6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21006—Coagulation factor Xa (3.4.21.6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)

Abstract

Настоящее изобретение относится к рекомбинантным полипептидам фактора свертывания Xa (Fxa), которые можно применять в качестве антидотов для полного или частичного обращения антикоагулянтного эффекта ингибитора свертывания крови у субъекта, предпочтительно прямого ингибитора фактора Xa. В настоящем документе раскрыты рекомбинантные белки фактора Xa и способ полного или частичного обращения антикоагулянтного эффекта ингибитора свертывания крови у субъекта.
EA201692161A 2014-05-26 2015-05-26 Прогемостатические белки для лечения кровотечений EA037991B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14169895 2014-05-26
PCT/NL2015/050377 WO2015183085A1 (en) 2014-05-26 2015-05-26 Prohemostatic proteins for the treatment of bleeding

Publications (2)

Publication Number Publication Date
EA201692161A1 true EA201692161A1 (ru) 2017-08-31
EA037991B1 EA037991B1 (ru) 2021-06-21

Family

ID=50774744

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201692161A EA037991B1 (ru) 2014-05-26 2015-05-26 Прогемостатические белки для лечения кровотечений
EA202190813A EA202190813A1 (ru) 2014-05-26 2015-05-26 Прогемостатические белки для лечения кровотечений

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA202190813A EA202190813A1 (ru) 2014-05-26 2015-05-26 Прогемостатические белки для лечения кровотечений

Country Status (25)

Country Link
US (4) US10537618B2 (ru)
EP (2) EP3744840A1 (ru)
JP (3) JP6640198B2 (ru)
KR (2) KR102245264B1 (ru)
CN (1) CN106536566A (ru)
AU (2) AU2015268149B2 (ru)
BR (1) BR112016027649A2 (ru)
CA (1) CA2949349A1 (ru)
DK (1) DK3149163T3 (ru)
EA (2) EA037991B1 (ru)
ES (1) ES2813440T3 (ru)
HR (1) HRP20201311T1 (ru)
HU (1) HUE052098T2 (ru)
IL (2) IL249132B (ru)
LT (1) LT3149163T (ru)
MA (2) MA51688A (ru)
MX (2) MX2016015567A (ru)
NZ (1) NZ727444A (ru)
PL (1) PL3149163T3 (ru)
PT (1) PT3149163T (ru)
RS (1) RS60706B1 (ru)
SG (2) SG11201609811TA (ru)
SI (1) SI3149163T1 (ru)
WO (1) WO2015183085A1 (ru)
ZA (1) ZA201608017B (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3149163T1 (sl) 2014-05-26 2020-10-30 Academisch Ziekenhuis Leiden Prohemostatski proteini za zdravljenje krvavitve
CN108486197B (zh) * 2018-03-06 2021-10-22 爱斯特（成都）生物制药股份有限公司 高纯度依度沙班中间体的制备方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4703004A (en) 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
ES2109336T3 (es) 1990-11-26 1998-01-16 Genetics Inst Expresion de pace en celulas huesped y metodos de utilizacion de la misma.
US6797492B2 (en) 1991-05-17 2004-09-28 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
DE4203965A1 (de) 1992-02-11 1993-08-12 Max Planck Gesellschaft Antidot fuer hirudin und synthetische thrombininhibitoren
AT404357B (de) 1995-06-13 1998-11-25 Immuno Ag Prothrombin-derivate
DE19605126A1 (de) 1996-02-12 1997-08-14 Basf Ag Thrombinmuteine als Antidot für Thrombininhibitoren
US6200955B1 (en) 1996-06-11 2001-03-13 Commonwealth Biotechnologies, Inc. Heparin binding peptides
US6624141B1 (en) 1999-03-17 2003-09-23 The Regents Of The University Of Michigan Protamine fragment compositions and methods of use
EP1728798A1 (en) 2005-06-01 2006-12-06 ZLB Behring GmbH Coagulation factor X polypeptides with modified activation properties
MX2008006313A (es) * 2005-11-15 2008-11-06 Philadelphia Children Hospital Metodos y composiciones para modular la hemostasia.
EP1820508A1 (en) * 2006-02-21 2007-08-22 CSL Behring GmbH Coagulation factor X polypeptides with modified activation properties
AU2008239586B2 (en) * 2007-04-13 2013-09-26 Catalyst Biosciences, Inc. Modified factor VII polypetides and uses thereof
PT2915564T (pt) * 2007-09-28 2021-02-09 Alexion Pharma Inc Antídotos para inibidores do fator xa e métodos de utilização dos mesmos
TWI465247B (zh) * 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
WO2011008885A1 (en) 2009-07-15 2011-01-20 Portola Pharmaceuticals, Inc. Unit dose formulation of antidotes for factor xa inhibitors and methods of using the same
IN2015DN01404A (ru) 2012-07-25 2015-07-03 Catalyst Biosciences Inc
ES2761730T3 (es) 2013-01-31 2020-05-20 Pfizer Composiciones y procedimientos para contrarrestar la inhibición del factor Xa
US10119101B2 (en) 2014-04-28 2018-11-06 Ecolab Usa Inc. Method of minimizing enzyme based aerosol mist using a pressure spray system
SI3149163T1 (sl) * 2014-05-26 2020-10-30 Academisch Ziekenhuis Leiden Prohemostatski proteini za zdravljenje krvavitve

Also Published As

Publication number Publication date
SG11201609811TA (en) 2016-12-29
KR20210054573A (ko) 2021-05-13
JP6640198B2 (ja) 2020-02-05
CA2949349A1 (en) 2015-12-03
MA51688A (fr) 2020-12-02
RS60706B1 (sr) 2020-09-30
US11304995B2 (en) 2022-04-19
PL3149163T3 (pl) 2020-12-28
NZ727444A (en) 2021-12-24
IL277377A (en) 2020-11-30
HUE052098T2 (hu) 2021-04-28
MX2020013410A (es) 2021-02-26
EA202190813A1 (ru) 2021-12-31
EA037991B1 (ru) 2021-06-21
EP3149163A1 (en) 2017-04-05
LT3149163T (lt) 2020-09-25
AU2015268149B2 (en) 2021-03-11
MA40042B1 (fr) 2020-08-31
ES2813440T3 (es) 2021-03-23
AU2015268149A1 (en) 2016-12-08
PT3149163T (pt) 2020-09-03
JP2022134139A (ja) 2022-09-14
CN106536566A (zh) 2017-03-22
AU2021203838B2 (en) 2023-03-02
BR112016027649A2 (pt) 2017-08-15
US20220288172A1 (en) 2022-09-15
KR102245264B1 (ko) 2021-04-28
JP2017522900A (ja) 2017-08-17
US20200138916A1 (en) 2020-05-07
IL277377B (en) 2021-10-31
EP3744840A1 (en) 2020-12-02
US10537618B2 (en) 2020-01-21
KR102351728B1 (ko) 2022-01-14
SG10201906329VA (en) 2019-08-27
AU2021203838A1 (en) 2021-07-08
KR20170020332A (ko) 2017-02-22
ZA201608017B (en) 2019-04-24
US20200138917A1 (en) 2020-05-07
WO2015183085A1 (en) 2015-12-03
US20170157223A1 (en) 2017-06-08
HRP20201311T1 (hr) 2020-12-11
DK3149163T3 (da) 2020-08-31
SI3149163T1 (sl) 2020-10-30
IL249132A0 (en) 2017-01-31
EP3149163B1 (en) 2020-06-03
JP2020062039A (ja) 2020-04-23
IL249132B (en) 2020-09-30
MX2016015567A (es) 2017-06-29
US11357836B2 (en) 2022-06-14

Similar Documents

Publication Publication Date Title
EA201791775A1 (ru) Цистеиновая протеаза
CY1124921T1 (el) Μεθοδοι για την εκχυλιση και τον καθαρισμο μη μετουσιωμενων πρωτεϊνων
EA201791168A1 (ru) Способы и составы для лечения сосудистых заболеваний глаз
EA201791773A1 (ru) Цистеиновая протеаза
EA201791866A1 (ru) Бициклические гетероциклы в качестве ингибиторов fgfr
EA201791460A1 (ru) N4-гидроксицитидин и связанные с ним производные и варианты противовирусного применения
EA201692539A1 (ru) Антитела и антигенсвязывающие фрагменты, которые специфично связываются с белком тау, ассоциированным с микротрубочками
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201690314A1 (ru) Анти-garp-белок и его применения
MY182667A (en) Food compositions comprising one or both of recombinant beta-lactoglobulin protein and recombinant alphalactalbumin protein
WO2017015622A8 (en) Gdf11 binding proteins and uses thereof
EA201692529A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
EA201691470A1 (ru) Белки, связывающие калликреин плазмы, и их применение для лечения наследственного ангионевротического отека
DK3197472T3 (da) Rekombinante phe-frie proteiner til anvendelse i behandlingen af phenylketonuri
EA201690159A1 (ru) Способы и композиции для лечения рака
IL254242A0 (en) Dual signaling fusion proteins and methods of using them to treat diseases
EA201791898A1 (ru) Новые антитела, связывающиеся с tfpi, и содержащая их композиция
EA201792418A1 (ru) Применение cd24 для снижения уровней холестерина липопротеинов низкой плотности
WO2014152946A3 (en) Polypeptides for treating and/or limiting influenza infection
MX2019005693A (es) Factor viii direccionado a los globulos rojos y metodo para su uso.
EA201692161A1 (ru) Прогемостатические белки для лечения кровотечений
MX2017000831A (es) Cuantificacion de tnfr2 : fc plegada erroneamente.
EA201491455A1 (ru) ЭФФЕКТОРЫ β-АРРЕСТИНА, КОМПОЗИЦИИ, ИХ СОДЕРЖАЩИЕ, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
PH12016501608A1 (en) Peptides and methods of use
EA201790537A1 (ru) Дипептидилкетоамидные соединения и их применение для лечения и/или предотвращения накопления жира